Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Characterizing the chordoma immune microenvironment and multiomic analysis of its response to EGFR and CDK4/6 inhibitors

EF 2023-24

Résumé
Dr. Gelareh Zadeh, Princess Margaret Cancer Centre, University of Toronto. Chordoma is an uncommon but devastating bone cancer of the skull base and spine affecting 8 out of every 10 million people per year. Our proposed research aims to further characterize the microenvironment of chordomas, particularly its immunologic component, and study the response of these tumours to promising immunotherapies. The project has three main objectives: (1) to characterize the different immune microenvironments of two distinct chordoma subtypes our group has previously identified; (2) to study the genomic response of chordomas to EGFR and CDK4/6 inhibitors; and (3) to assess which cells within chordoma are responsible for resistance to treatment and recurrence by "tracking" these cells and examining their gene expression. We will focus on a subtype we previous identified as being infiltrated with immune cells, which has a significantly poorer overall survival. Through advanced sequencing techniques, we aim to better understand the role of immune cells in chordoma and the reason for the association of the immune-infiltrated subtype with a poor prognosis. We will also examine the genetic and protein response of chordomas to EGFR and CDK4/6 inhibitors to understand their mechanism and to predict patient response to these therapies. This project has the potential to improve our understanding of chordomas, their immune microenvironments, the biology behind their treatment responsiveness and to advance the development of effective immunotherapies for this aggressive cancer.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
495737
Name
Gui Chloe
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Characterizing the chordoma immune microenvironment and multiomic analysis of its response to EGFR and CDK4/6 inhibitors
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Brain Tumour; Chordoma; Crispr Lineage Tracing; Immunotherapy; Methylation, Proteomics, Genomics; Molecular Biology; Tumour Genetics
Abstract
Dr. Gelareh Zadeh, Princess Margaret Cancer Centre, University of Toronto. Chordoma is an uncommon but devastating bone cancer of the skull base and spine affecting 8 out of every 10 million people per year. Our proposed research aims to further characterize the microenvironment of chordomas, particularly its immunologic component, and study the response of these tumours to promising immunotherapies. The project has three main objectives: (1) to characterize the different immune microenvironments of two distinct chordoma subtypes our group has previously identified; (2) to study the genomic response of chordomas to EGFR and CDK4/6 inhibitors; and (3) to assess which cells within chordoma are responsible for resistance to treatment and recurrence by "tracking" these cells and examining their gene expression. We will focus on a subtype we previous identified as being infiltrated with immune cells, which has a significantly poorer overall survival. Through advanced sequencing techniques, we aim to better understand the role of immune cells in chordoma and the reason for the association of the immune-infiltrated subtype with a poor prognosis. We will also examine the genetic and protein response of chordomas to EGFR and CDK4/6 inhibitors to understand their mechanism and to predict patient response to these therapies. This project has the potential to improve our understanding of chordomas, their immune microenvironments, the biology behind their treatment responsiveness and to advance the development of effective immunotherapies for this aggressive cancer.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gui, Chloe
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~